Key achievements and impact
2023
Professor Ramanan was the Chief Investigator of a NIHR portfolio study which has demonstrated efficacy of baricitinib as an oral molecule as effective as biologics for children with refractory arthritis. This study has led to EMA approval for baricitinib for children with arthritis. It is expected this manuscript (published in 2023)and the approval of this agent will have a significant impact on outcomes of arthritis in children.
Ramanan AV et. al. Lancet. 2023 Jul 6:S0140-6736(23)00921-2
2022
Dr Sarah Clarke has been named a “Rising Star in Paediatric Rheumatology"
The CLUSTER Consortium has been awarded £5million from the MRC with partnership funding from Arthritis Research UK
The Sycamore study led by Bristol has led to access to adalimumab for children with uveitis across the world. More than 80 countries have used the Sycamore data to approve this drug for children with uveitis. It is one of the impact case studies put forward by University of Bristol for REF 2021.
2021
Dr Sarah Clarke has been awarded the Sam Tucker Fellowship from the Royal Society of Medicine
2020
Results of the APTITUDE trial have been published in the Lancet
2018
Prof Ramanan has been awarded the RCP/NIHR CRN Consultant Award for outstanding contribution to research
Dr Sarah Clarke has been named a “Rising Star in Paediatric Rheumatology” at The CLUSTER Consortium has been awarded £5million from the MRC with partnership funding from Arthritis Research UK
2017
Results of the SYCAMORE trial have been published in the NEJM
Dr Sarah Clarke has been awarded a doctoral training fellowship by the Wellcome Trust GW4 CAT programme
2015
NHS announces clinical commissioning policy on adalimumab for children with uveitis following the results of the SYCAMORE trial.
Dr Sarah Clarke successfully obtained a competitive small project grant from Above and Beyond Charities to support her research fellowship at the National Institutes of Health, USA.